MCID: SNS003
MIFTS: 57

Sensory Peripheral Neuropathy

Categories: Neuronal diseases

Aliases & Classifications for Sensory Peripheral Neuropathy

MalaCards integrated aliases for Sensory Peripheral Neuropathy:

Name: Sensory Peripheral Neuropathy 12 15
Sensory Neuropathy 12 76 29 55 6 15 73
Hereditary Sensory and Autonomic Neuropathies 73
Peripheral Sensory Neuropathy 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2491
ICD9CM 35 356.2
MeSH 44 D009477
NCIt 50 C3501
SNOMED-CT 68 11442006 95662005

Summaries for Sensory Peripheral Neuropathy

Disease Ontology : 12 A neuropathy that involves damage to nerves of the peripheral nervous system.

MalaCards based summary : Sensory Peripheral Neuropathy, also known as sensory neuropathy, is related to hereditary motor and sensory neuropathy, type iic and sensory neuropathy type 1, and has symptoms including hyperesthesia, dysesthesia and sciatica. An important gene associated with Sensory Peripheral Neuropathy is MPZ (Myelin Protein Zero), and among its related pathways/superpathways are Brain-Derived Neurotrophic Factor (BDNF) signaling pathway and Guidance Cues and Growth Cone Motility. The drugs Lidocaine and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and colon, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Peripheral neuropathy (PN) is damage to or disease affecting nerves, which may impair sensation,... more...

Related Diseases for Sensory Peripheral Neuropathy

Diseases related to Sensory Peripheral Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
# Related Disease Score Top Affiliating Genes
1 hereditary motor and sensory neuropathy, type iic 33.7 GDAP1 GJB1 MFN2 MPZ
2 sensory neuropathy type 1 33.7 GJB1 SPTLC1
3 charcot-marie-tooth disease, demyelinating, type 1b 33.2 PMP22 MTMR2 MPZ GJB1 EGR2
4 roussy-levy hereditary areflexic dystasia 33.0 MPZ PMP22
5 charcot-marie-tooth disease, demyelinating, type 1c 32.9 PMP22 MPZ LITAF GJB1 EGR2
6 charcot-marie-tooth disease, type 4d 32.8 GDAP1 GJB1 MFN2 NTF3
7 charcot-marie-tooth disease, demyelinating, type 1a 32.7 PMP22 NTF3 MTMR2 MPZ MFN2 GJB1
8 charcot-marie-tooth disease, demyelinating, type 1d 32.6 EGR2 GJB1 MPZ MTMR2 PMP22
9 charcot-marie-tooth disease 32.4 SPTLC1 PRX PMP22 MTMR2 MPZ MFN2
10 charcot-marie-tooth disease, axonal, type 2d 32.4 GJB1 MPZ PMP22
11 charcot-marie-tooth disease, type 4b2 32.3 GDAP1 MTMR2 PRX
12 charcot-marie-tooth disease, type 4a 32.3 GDAP1 MTMR2 PRX
13 charcot-marie-tooth disease, type 4b1 32.3 GDAP1 MTMR2 PRX
14 motor peripheral neuropathy 32.3 SLC12A6 PMP22 MTMR2 MPZ MFN2 GJB1
15 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 32.3 SLC12A6 PRX PMP22 MTMR2 MPZ MFN2
16 charcot-marie-tooth disease, axonal, type 2e 32.3 SLC12A6 PMP22 MTMR2 MPZ MFN2 GJB1
17 neuropathy - hereditary 32.1 MPZ PMP22 SPTLC1
18 charcot-marie-tooth disease, axonal, type 2b 32.1 MPZ GJB1 EGR2 PMP22 SPTLC1
19 charcot-marie-tooth disease and deafness 32.0 PMP22 NTF3 MTMR2 MPZ MFN2 LITAF
20 charcot-marie-tooth disease, x-linked dominant, 1 32.0 GJB1 MPZ PMP22
21 charcot-marie-tooth hereditary neuropathy 32.0 MPZ PMP22
22 neuropathy, hereditary, with liability to pressure palsies 31.9 PMP22 MTMR2 MPZ MFN2 LITAF GJB1
23 hypertrophic neuropathy of dejerine-sottas 31.1 PRX PMP22 MTMR2 MPZ LITAF GJB1
24 charcot-marie-tooth disease, demyelinating, type 1f 30.8 GJB1 MPZ PMP22
25 charcot-marie-tooth disease, axonal, type 2f 30.8 GJB1 MPZ
26 charcot-marie-tooth disease, type 4b3 30.7 GDAP1 MTMR2
27 charcot-marie-tooth disease, demyelinating, type 4f 30.7 GDAP1 MTMR2 PRX
28 charcot-marie-tooth disease, axonal, type 2q 30.7 EGR2 MPZ
29 polyneuropathy 30.2 GDAP1 MAG MPZ PMP22
30 tooth disease 30.0 PRX PMP22 MTMR2 MPZ MFN2 LITAF
31 demyelinating polyneuropathy 30.0 MAG NGF PMP22
32 neuropathy 30.0 SPTLC1 SLC12A6 PRX PMP22 NGF MPZ
33 amyotrophic neuralgia 29.9 GJB1 PMP22 PRX
34 neuritis 29.9 MAG MPZ PMP22
35 axonal neuropathy 29.9 GDAP1 MFN2 PMP22
36 peripheral nervous system disease 29.6 SPTLC1 SLC12A6 PRX PMP22 NGF MTMR2
37 hereditary motor and sensory neuropathy v 12.5
38 hereditary sensory neuropathy 12.5
39 deafness, nerve type, with mesenteric diverticula of small bowel and progressive sensory neuropathy 12.3
40 hereditary motor and sensory neuropathy with acrodystrophy 12.3
41 motor sensory neuropathy type 1 aplasia cutis congenita 12.3
42 dnmt1-related dementia, deafness, and sensory neuropathy 12.2
43 hereditary motor and sensory neuropathy with agenesis of the corpus callosum 12.2
44 neuropathy, hereditary motor and sensory, okinawa type 12.2
45 agenesis of the corpus callosum with peripheral neuropathy 12.1
46 neuropathy, hereditary motor and sensory, type via 12.1
47 keratoderma, palmoplantar, with nail dystrophy and hereditary motor-sensory neuropathy 12.1
48 gdap1-related hereditary motor and sensory neuropathy 12.1
49 acute pure sensory neuropathy 12.1
50 infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome 12.1

Graphical network of the top 20 diseases related to Sensory Peripheral Neuropathy:



Diseases related to Sensory Peripheral Neuropathy

Symptoms & Phenotypes for Sensory Peripheral Neuropathy

UMLS symptoms related to Sensory Peripheral Neuropathy:


hyperesthesia, dysesthesia, sciatica, neurologic symptoms

GenomeRNAi Phenotypes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

26 (show all 40)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.42 GJB1
2 Decreased viability GR00221-A-1 10.42 ELAVL4 FXN
3 Decreased viability GR00221-A-2 10.42 ELAVL4
4 Decreased viability GR00301-A 10.42 FXN
5 Decreased viability GR00381-A-1 10.42 FGD4 MPZ PRX
6 Decreased viability GR00381-A-3 10.42 MPZ
7 Decreased viability GR00402-S-2 10.42 CCT4 EGR2 ELAVL3 ELAVL4 FGD4 FLVCR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.19 FGD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.19 FGD4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.19 SLC12A6
11 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.19 NTF3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.19 FGD4 GJB1 NTF3 SLC12A6
13 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.19 NTF3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.19 FGD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.19 FGD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.19 GJB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.19 FGD4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.19 NTF3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.19 GJB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.19 GJB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.19 SLC12A6
22 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.19 NTF3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.19 FGD4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.19 GJB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.19 SLC12A6
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.19 GJB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.19 SLC12A6
28 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.19 SLC12A6
29 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.19 SLC12A6
30 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.19 GJB1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.19 GJB1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10.19 FGD4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.19 NTF3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.19 SLC12A6
35 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.19 SLC12A6
36 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.19 NTF3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.19 FGD4
38 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.19 SLC12A6
39 Increased gamma-H2AX phosphorylation GR00053-A 9.76 CCT4 EGR2 ELAVL4 GJB1 MAG MPZ
40 no effect GR00402-S-1 9.62 CCT4 EGR2 ELAVL3 ELAVL4 FGD4 FLVCR1

MGI Mouse Phenotypes related to Sensory Peripheral Neuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 EGR2 ELAVL3 ELAVL4 FGD4 FXN GDAP1
2 homeostasis/metabolism MP:0005376 10.13 EGR2 ELAVL3 ELAVL4 FLVCR1 FXN GDAP1
3 cellular MP:0005384 10.07 EGR2 ELAVL4 FXN GDAP1 GJB1 LITAF
4 growth/size/body region MP:0005378 10.06 EGR2 FLVCR1 FXN GJB1 MFN2 MTMR2
5 mortality/aging MP:0010768 9.97 EGR2 ELAVL3 ELAVL4 FLVCR1 FXN GJB1
6 nervous system MP:0003631 9.91 EGR2 ELAVL3 ELAVL4 FGD4 FXN GDAP1
7 reproductive system MP:0005389 9.28 EGR2 ELAVL4 FLVCR1 MPZ MTMR2 NTF3

Drugs & Therapeutics for Sensory Peripheral Neuropathy

Drugs for Sensory Peripheral Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
3
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
4
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 13422-55-4
5
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 11953898 44475014
6
leucovorin Approved Phase 4,Phase 3,Not Applicable 58-05-9 6006 143
7
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 65-23-6 1054
8
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4,Not Applicable 54-47-7 1051
9
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 68-19-9 44176380
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-30-3 6037
11
Cobalamin Experimental Phase 4,Phase 3,Not Applicable 13408-78-1 6438156
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Diuretics, Potassium Sparing Phase 4,Not Applicable
15 GABA Agents Phase 4
16 Excitatory Amino Acid Antagonists Phase 4,Phase 3
17 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
18 Antiparkinson Agents Phase 4
19 Excitatory Amino Acids Phase 4,Phase 3
20 Anesthetics, Local Phase 4
21 calcium channel blockers Phase 4,Phase 3
22 Anticonvulsants Phase 4,Phase 3,Phase 2
23 Anesthetics Phase 4,Phase 3
24 Anti-Arrhythmia Agents Phase 4,Phase 3
25 Anti-Anxiety Agents Phase 4
26 Antimanic Agents Phase 4
27 Sodium Channel Blockers Phase 4,Not Applicable
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Calcium, Dietary Phase 4,Phase 3
30 Tranquilizing Agents Phase 4,Phase 3,Phase 2
31 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
32 Vitamin B 12 Phase 4,Phase 3,Not Applicable
33 Vitamin B9 Phase 4,Phase 3,Phase 2,Not Applicable
34 Vitamin B 6 Phase 4,Phase 3,Not Applicable
35 Vitamin B Complex Phase 4,Phase 3,Phase 2,Not Applicable
36 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Folate Phase 4,Phase 3,Phase 2,Not Applicable
38 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Vitamin B12 Phase 4,Phase 3,Not Applicable
41
Pyridoxal Experimental, Nutraceutical Phase 4,Phase 3,Not Applicable 66-72-8 1050
42
Carboplatin Approved Phase 3,Not Applicable 41575-94-4 10339178 38904 498142
43
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
44
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
45
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
46
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
47
Acetylcarnitine Approved, Investigational Phase 3 3040-38-8 1
48
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
49
Fluorouracil Approved Phase 3,Not Applicable 51-21-8 3385
50
Oxaliplatin Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 61825-94-3 43805 6857599 5310940 9887054

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 Anodyne Therapy in Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
2 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
3 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
4 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
5 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
6 Clinical Study on Acetyl-L-Carnitine Completed NCT01526564 Phase 3 Acetylcarnitine;Placebo
7 Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer Completed NCT00363129 Phase 3
8 XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy Completed NCT00272051 Phase 3 SR57746A
9 Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Completed NCT00305188 Phase 3 Xaliproden (SR57746A);Placebo;Oxaliplatin;5-Fluorouracil;Leucovorin
10 Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity Completed NCT01087658 Phase 3 Glutamine;Calcium and Magnesium
11 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
12 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
13 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3 Ganglioside-monosialic acid;placebo
14 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients Completed NCT00659269 Phase 3 Chemotherapy
15 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
16 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Completed NCT00791492 Phase 2, Phase 3 Fx-1006A
17 Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer Recruiting NCT02289547 Phase 3 Capecitabine
18 PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA Recruiting NCT03006432 Phase 3 Oxaliplatin;5Fluorouracil bolus;5Fluorouracil continu;Docetaxel;Folinic Acid
19 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
20 Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies Not yet recruiting NCT03700138 Phase 3 Privigen® 100mg/ml at the dose of 2g/kg of body weight;NaCl 0,9%
21 Treatment of Chronic Laryngitis With Amitriptyline Suspended NCT02552225 Phase 2, Phase 3 Amitriptyline
22 Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens Terminated NCT00603577 Phase 3 Placebo;Xaliproden
23 Trial of the Treatment of Chronic Laryngitis With Amitryptiline Terminated NCT02434523 Phase 2, Phase 3 Amitriptyline
24 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
25 Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402) Unknown status NCT02288078 Phase 2 Dexamethasone;Regorafenib;Placebo;Proton pump inhibitor
26 A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy Completed NCT00000842 Phase 2 Nerve Growth Factor, Recombinant Human
27 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1 Completed NCT01733407 Phase 1, Phase 2 L-serine;placebo
28 Ascorbic Acid Treatment in CMT1A Trial (AATIC) Completed NCT00271635 Phase 2 Placebo;ascorbic acid
29 Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy Completed NCT00952848 Phase 2
30 Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel Completed NCT02297412 Phase 2 Minocycline Hydrochloride
31 Effect of C-Peptide on Diabetic Peripheral Neuropathy Completed NCT00278980 Phase 2 C-peptide
32 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed NCT00061893 Phase 2 celecoxib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vinblastine sulfate;vincristine sulfate;MESNA;Filgrastim
33 Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A Completed NCT01401257 Phase 2 PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose
34 Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma Completed NCT00153920 Phase 2 bortezomib
35 Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma Completed NCT00287872 Phase 2 bortezomib;thalidomide
36 Cetuximab and Lenalidomide in Head and Neck Completed NCT01133665 Phase 2 Cetuximab and Lenalidomide
37 Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy Completed NCT01469559 Phase 2 Novolin Toronto insulin;Normal saline
38 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN) Recruiting NCT02878798 Phase 2 topiramate
39 The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Recruiting NCT02915263 Phase 2 IGIV-C;0.9% Sodium Chloride
40 Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer Recruiting NCT03502343 Phase 2 Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy
41 IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3 Recruiting NCT03401073 Phase 2 Intravenous immunoglobulin;0.9% Sodium Chloride
42 NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma Recruiting NCT03524898 Phase 1, Phase 2 Nab-Paclitaxel;gemcitabine
43 NR in Chemo-induced Peripheral Neuropathy Not yet recruiting NCT03642990 Phase 2 Nicotinamide Riboside
44 A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy Terminated NCT00267007 Phase 2 PROCRIT 40,000 IU QW;Placebo
45 NB2013-HR German (GPOH) / Dutch (DCOG) Trial Terminated NCT02641782 Phase 2 antibody ch14.18;GM-CSF;IL-2 i.v.;IL-2 s.c.;Retinoic acid
46 Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma Terminated NCT00372905 Phase 1, Phase 2 rituximab;bortezomib;Ibritumomab tiuxetan
47 Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient Terminated NCT01955629 Phase 1, Phase 2 Aflibercept AVE0005;Oxaliplatin;Capecitabine
48 Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS) Terminated NCT00231140 Phase 2 Thalidomide (drug)
49 Epoetin Alfa for HIV-Associated Neuropathy Trial Withdrawn NCT00528593 Phase 2 epoetin alfa
50 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed NCT00258245 Phase 1 arsenic trioxide;bortezomib;dexamethasone;thalidomide;Aspirin

Search NIH Clinical Center for Sensory Peripheral Neuropathy

Genetic Tests for Sensory Peripheral Neuropathy

Genetic tests related to Sensory Peripheral Neuropathy:

# Genetic test Affiliating Genes
1 Sensory Neuropathy 29

Anatomical Context for Sensory Peripheral Neuropathy

MalaCards organs/tissues related to Sensory Peripheral Neuropathy:

41
Skin, Lung, Colon, Testes, Bone, Spinal Cord, Brain

Publications for Sensory Peripheral Neuropathy

Articles related to Sensory Peripheral Neuropathy:

(show top 50) (show all 1028)
# Title Authors Year
1
Diagnosis of Pure Ulnar Sensory Neuropathy Around the Hypothenar Area Using Orthodromic Inching Sensory Nerve Conduction Study: A Case Report. ( 29961748 )
2018
2
An Isolated Trigeminal Sensory Neuropathy. ( 29977447 )
2018
3
Hereditary sensory neuropathy type 1-associated deoxysphingolipids cause neurotoxicity, acute calcium handling abnormalities and mitochondrial dysfunction in vitro. ( 29778900 )
2018
4
Post-infectious sensory neuropathy with anti-GT1a and GQ1b antibodies associated with cold urticaria. ( 30318072 )
2018
5
Identification of a novel SLC12A6 pathogenic variant associated with hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC) in a non-French-Canadian family. ( 30038111 )
2018
6
BICD2 mutational analysis in hereditary spastic paraplegia and hereditary motor and sensory neuropathy. ( 30536747 )
2018
7
Codeine-Induced Sensory Neuropathy, Autonomic Dysfunction, and Myopathy. ( 30024635 )
2018
8
SACS variants are a relevant cause of autosomal recessive hereditary motor and sensory neuropathy. ( 30460542 )
2018
9
A novel nonsense mutation in WNK1/HSN2 associated with sensory neuropathy and limb destruction in four siblings of a large Iranian pedigree. ( 30497409 )
2018
10
Validation of diagnostic methods for traumatic sensory neuropathy and neuropathic pain. ( 30549060 )
2018
11
Recurrent autonomic and sensory neuropathy in a patient with anti-ganglionic acetylcholine receptor antibodies. ( 30211328 )
2018
12
Pharmacogenetic variation influences sensory neuropathy occurrence in Southern Africans treated with stavudine-containing antiretroviral therapy. ( 30273369 )
2018
13
Two mixed breed dogs with sensory neuropathy are homozygous for an inversion disrupting FAM134B previously identified in Border Collies. ( 30307654 )
2018
14
Sensory neuropathy-causing mutations in ATL3 affect ER-mitochondria contact sites and impair axonal mitochondrial distribution. ( 30339187 )
2018
15
Detectable Plasma HIV RNA Is Associated With Sensory Neuropathy in Patients With HIV Treated Without Stavudine. ( 30371533 )
2018
16
The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. ( 30043209 )
2018
17
The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: A randomized clinical trial. ( 30057636 )
2018
18
Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy via block of N- and T-type calcium channels. ( 30169422 )
2018
19
Reduced intraepidermal nerve fibre density, glial activation, and sensory changes in HIV type-1 Tat-expressing female mice: involvement of Tat during early stages of HIV-associated painful sensory neuropathy. ( 29922746 )
2018
20
Sensory-Neuropathy-Causing Mutations in ATL3 Cause Aberrant ER Membrane Tethering. ( 29768202 )
2018
21
The natural history of hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) in 97 Japanese patients. ( 29552439 )
2018
22
Arterial Stiffness Is Associated with Peripheral Sensory Neuropathy in Diabetes Patients in Ghana. ( 29629375 )
2018
23
Inflammation role in sensory neuropathy in Chinese patients with diabetes/prediabetes. ( 29414152 )
2018
24
Polymorphisms in P2X4R and CAMKK2 may affect TNFα production: Implications for a role in HIV-associated sensory neuropathy. ( 29428485 )
2018
25
Evolution of sensory neuropathy after initiation of antiretroviral therapy. ( 28561925 )
2018
26
Isolated trigeminal sensory neuropathy during etanercept therapy: A case report. ( 28602437 )
2018
27
Letter regarding the article: "A novel missense variant (Gln220Arg) of GNB4 encoding guanine nucleotide-binding protein, subunit beta-4 in a Japanese family with autosomal dominant motor and sensory neuropathy". ( 28705522 )
2018
28
Psychological Factors Associated With Painful Versus Non-Painful HIV-Associated Sensory Neuropathy. ( 28710709 )
2018
29
Ex-vivo expression of chemokine receptors on cells surrounding cutaneous nerves in patients with HIV-associated sensory neuropathy. ( 29239897 )
2018
30
POLG2 deficiency causes adult-onset syndromic sensory neuropathy, ataxia and parkinsonism. ( 28078310 )
2017
31
Cyclic vomiting syndrome after acute autonomic and sensory neuropathy. ( 28244649 )
2017
32
[Clinical and epidemiological characteristics of hereditary motor-sensory neuropathy 1X caused by the mutation c. 259C> G (p. P87A) in the GJB1 gene of patients from the Republic of Bashkortostan]. ( 28399101 )
2017
33
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. ( 28447211 )
2017
34
Structure of the human TRiC/CCT Subunit 5 associated with hereditary sensory neuropathy. ( 28623285 )
2017
35
A novel missense variant (Gln220Arg) of GNB4 encoding guanine nucleotide-binding protein, subunit beta-4 in a Japanese family with autosomal dominant motor and sensory neuropathy. ( 28642160 )
2017
36
Jumping Mechanography as a Complementary Testing Tool for Motor Function in Children with Hereditary Motor and Sensory Neuropathy. ( 28641335 )
2017
37
Sensory neuropathy in progressive motor neuronopathy (pmn) mice is associated with defects in microtubule polymerization and axonal transport. ( 27488538 )
2017
38
Charcot Marie Tooth 2B Peripheral Sensory Neuropathy: How Rab7 Mutations Impact NGF Signaling? ( 28165391 )
2017
39
Sensory neuropathy in a patient with low low-density lipoprotein cholesterol levels. ( 28345230 )
2017
40
Peripheral Sensory Neuropathy and associated factors among adult diabetes mellitus patients in Bahr Dar, Ethiopia. ( 28396852 )
2017
41
A Novel Ataxic Mutant Mouse Line Having Sensory Neuropathy Shows Heavy Iron Deposition in Kidney. ( 28490024 )
2017
42
Genetics of HIV-associated sensory neuropathy and related pain in Africans. ( 28560631 )
2017
43
Chronic non-freezing cold injury results in neuropathic pain due to a sensory neuropathy. ( 28969380 )
2017
44
Single Nucleotide Polymorphisms of Paclitaxel-induced Peripheral Sensory Neuropathy in Chinese Han Population. ( 29125099 )
2017
45
A homozygous FITM2 mutation causes a deafness-dystonia syndrome with motor regression and signs of ichthyosis and sensory neuropathy. ( 28067622 )
2016
46
Prevalence of Sensory Neuropathy in Type 2 Diabetes Mellitus and Its Correlation with Duration of Disease. ( 28166066 )
2016
47
Compound heterozygous intermediate MJD alleles cause cerebellar ataxia with sensory neuropathy. ( 27896316 )
2016
48
TNF Block Gene Variants Associate With Pain Intensity in Black Southern Africans With HIV-associated Sensory Neuropathy. ( 25756557 )
2016
49
Severe sensory neuropathy in patients with adult-onset multiple acyl-CoA dehydrogenase deficiency. ( 26821934 )
2016
50
Painless Ulcers and Fissures of Toes: Hereditary Sensory Neuropathy, Not Leprosy. ( 26955138 )
2016

Variations for Sensory Peripheral Neuropathy

ClinVar genetic disease variations for Sensory Peripheral Neuropathy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh37 Chromosome 8, 75276240: 75276240
2 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh38 Chromosome 8, 74364005: 74364005
3 MPZ NM_000530.7(MPZ): c.293G> A (p.Arg98His) single nucleotide variant Pathogenic/Likely pathogenic rs121913589 GRCh37 Chromosome 1, 161276653: 161276653
4 MPZ NM_000530.7(MPZ): c.293G> A (p.Arg98His) single nucleotide variant Pathogenic/Likely pathogenic rs121913589 GRCh38 Chromosome 1, 161306863: 161306863
5 SPTLC3 NM_018327.3(SPTLC3): c.448T> C (p.Trp150Arg) single nucleotide variant Likely pathogenic rs755919784 GRCh38 Chromosome 20, 13072400: 13072400
6 SPTLC3 NM_018327.3(SPTLC3): c.448T> C (p.Trp150Arg) single nucleotide variant Likely pathogenic rs755919784 GRCh37 Chromosome 20, 13053048: 13053048
7 POMT1 NM_007171.3(POMT1): c.1859G> A (p.Arg620Gln) single nucleotide variant Uncertain significance rs202140413 GRCh37 Chromosome 9, 134396827: 134396827
8 POMT1 NM_007171.3(POMT1): c.1859G> A (p.Arg620Gln) single nucleotide variant Uncertain significance rs202140413 GRCh38 Chromosome 9, 131521440: 131521440
9 GJB1 NM_001097642.2(GJB1): c.502T> G (p.Cys168Gly) single nucleotide variant Likely pathogenic rs1057518780 GRCh37 Chromosome X, 70444059: 70444059
10 GJB1 NM_001097642.2(GJB1): c.502T> G (p.Cys168Gly) single nucleotide variant Likely pathogenic rs1057518780 GRCh38 Chromosome X, 71224209: 71224209

Expression for Sensory Peripheral Neuropathy

Search GEO for disease gene expression data for Sensory Peripheral Neuropathy.

Pathways for Sensory Peripheral Neuropathy

Pathways related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 EGR2 NGF NTF3
2 11.4 GDAP1 MAG NGF
3 11.14 GJB1 MPZ PMP22
4
Show member pathways
10.62 MAG NGF NTF3

GO Terms for Sensory Peripheral Neuropathy

Cellular components related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synaptic vesicle GO:0008021 9.13 MTMR2 NGF NTF3
2 compact myelin GO:0043218 8.62 MAG PMP22

Biological processes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.61 MAG NGF NTF3
2 mitochondrial fusion GO:0008053 9.4 GDAP1 MFN2
3 nerve development GO:0021675 9.37 NGF NTF3
4 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.32 MAG MPZ
5 nerve growth factor signaling pathway GO:0038180 9.26 NGF NTF3
6 myelin assembly GO:0032288 9.16 MTMR2 PMP22
7 myelination GO:0042552 9.13 EGR2 MPZ PMP22
8 peripheral nervous system development GO:0007422 8.92 EGR2 NGF NTF3 PMP22

Molecular functions related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 AU-rich element binding GO:0017091 8.62 ELAVL3 ELAVL4

Sources for Sensory Peripheral Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....